TY  - JOUR
AU  - Castaño-Bonilla, Tamara
AU  - Barragán, Eva
AU  - Sargas, Claudia
AU  - Sanz, Alejandro
AU  - Algarra, Lorenzo
AU  - Herrera-Puente, Pilar
AU  - García-Boyero, Raimundo
AU  - Barrios, Manuel
AU  - Martinez-Cuadron, David
AU  - Rodriguez-Veiga, Rebeca
AU  - Boluda, Blanca
AU  - Gil, Cristina
AU  - Serrano-López, Josefina
AU  - Martínez-López, Joaquín
AU  - Sayas-Lloris, María José
AU  - Olave, María Teresa
AU  - Riaza-Grau, Rosalía
AU  - Castillo, Teresa Bernal-Del
AU  - Larrayoz, María José
AU  - Amigo, Raquel
AU  - Jiménez-Velasco, Antonio
AU  - Sánchez, Joaquín
AU  - Ayala, Rosa
AU  - Blas, Carlos
AU  - Lainez, Daniel
AU  - Serrano-López, Juana
AU  - Sanz, Miguel A
AU  - Alonso-Domínguez, Juan M
AU  - Montesinos, Pau
PY  - 2022
DO  - 10.1155/2022/3132941
UR  - http://hdl.handle.net/10668/20173
T2  - Disease markers
AB  - Gemtuzumab ozogamicin (GO) is a conjugate of a monoclonal antibody and calicheamicin, which has been reapproved for the treatment of acute myeloid leukemia (AML). AML patients with the CD33 rs12459419 CC genotype might benefit from the addition of GO...
LA  - en
KW  - Aminoglycosides
KW  - Antibodies, Monoclonal, Humanized
KW  - Gemtuzumab
KW  - Humans
KW  - Leukemia, Myeloid, Acute
KW  - Polymorphism, Single Nucleotide
KW  - Sialic Acid Binding Ig-like Lectin 3
TI  - No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group.
TY  - research article
VL  - 2022
ER  -